162 related articles for article (PubMed ID: 33089889)
1. At the Bedside: Profiling and treating patients with CXCR4-expressing cancers.
Martin M; Mayer IA; Walenkamp AME; Lapa C; Andreeff M; Bobirca A
J Leukoc Biol; 2021 May; 109(5):953-967. PubMed ID: 33089889
[TBL] [Abstract][Full Text] [Related]
2. Chemokine receptor - Directed imaging and therapy.
Buck AK; Stolzenburg A; Hänscheid H; Schirbel A; Lückerath K; Schottelius M; Wester HJ; Lapa C
Methods; 2017 Nov; 130():63-71. PubMed ID: 28916148
[TBL] [Abstract][Full Text] [Related]
3. CXCR4 inhibitors: tumor vasculature and therapeutic challenges.
de Nigris F; Schiano C; Infante T; Napoli C
Recent Pat Anticancer Drug Discov; 2012 Sep; 7(3):251-64. PubMed ID: 22376154
[TBL] [Abstract][Full Text] [Related]
4. The chemokine receptors CXCR4/CXCR7 and their primary heterodimeric ligands CXCL12 and CXCL12/high mobility group box 1 in pancreatic cancer growth and development: finding flow.
Shakir M; Tang D; Zeh HJ; Tang SW; Anderson CJ; Bahary N; Lotze MT
Pancreas; 2015 May; 44(4):528-34. PubMed ID: 25872129
[TBL] [Abstract][Full Text] [Related]
5. CXCR4 receptor as a promising target for oncolytic drugs.
Lavrovsky Y; Ivanenkov YA; Balakin KV; Medvedeva DA; Ivachtchenko AV
Mini Rev Med Chem; 2008 Oct; 8(11):1075-87. PubMed ID: 18855724
[TBL] [Abstract][Full Text] [Related]
6. Molecular Pathways: Targeting the CXCR4-CXCL12 Axis--Untapped Potential in the Tumor Microenvironment.
Scala S
Clin Cancer Res; 2015 Oct; 21(19):4278-85. PubMed ID: 26199389
[TBL] [Abstract][Full Text] [Related]
7. At the Bench: Pre-clinical evidence for multiple functions of CXCR4 in cancer.
Luker GD; Yang J; Richmond A; Scala S; Festuccia C; Schottelius M; Wester HJ; Zimmermann J
J Leukoc Biol; 2021 May; 109(5):969-989. PubMed ID: 33104270
[TBL] [Abstract][Full Text] [Related]
8. Identification of LY2510924, a novel cyclic peptide CXCR4 antagonist that exhibits antitumor activities in solid tumor and breast cancer metastatic models.
Peng SB; Zhang X; Paul D; Kays LM; Gough W; Stewart J; Uhlik MT; Chen Q; Hui YH; Zamek-Gliszczynski MJ; Wijsman JA; Credille KM; Yan LZ
Mol Cancer Ther; 2015 Feb; 14(2):480-90. PubMed ID: 25504752
[TBL] [Abstract][Full Text] [Related]
9. The CXCL12/CXCR4 axis as a therapeutic target in cancer and HIV-1 infection.
Patrussi L; Baldari CT
Curr Med Chem; 2011; 18(4):497-512. PubMed ID: 21143114
[TBL] [Abstract][Full Text] [Related]
10. The CXCL12 (SDF-1)/CXCR4 chemokine axis: Oncogenic properties, molecular targeting, and synthetic and natural product CXCR4 inhibitors for cancer therapy.
Zhou Y; Cao HB; Li WJ; Zhao L
Chin J Nat Med; 2018 Nov; 16(11):801-810. PubMed ID: 30502762
[TBL] [Abstract][Full Text] [Related]
11. Structural Basis of the Binding Mode of the Antineoplastic Compound Motixafortide (BL-8040) in the CXCR4 Chemokine Receptor.
Rebolledo-Bustillo M; Garcia-Gomez D; Dávila EM; Castro ME; Caballero NA; Melendez FJ; Baizabal-Aguirre VM; Sanchez-Gaytan BL; Perez-Aguilar JM
Int J Mol Sci; 2023 Feb; 24(5):. PubMed ID: 36901829
[TBL] [Abstract][Full Text] [Related]
12. Potential of CXCR4 antagonists for the treatment of metastatic lung cancer.
Burger JA; Stewart DJ; Wald O; Peled A
Expert Rev Anticancer Ther; 2011 Apr; 11(4):621-30. PubMed ID: 21504328
[TBL] [Abstract][Full Text] [Related]
13. CXCR4 Ligands: The Next Big Hit?
Walenkamp AME; Lapa C; Herrmann K; Wester HJ
J Nucl Med; 2017 Sep; 58(Suppl 2):77S-82S. PubMed ID: 28864616
[TBL] [Abstract][Full Text] [Related]
14. Ulocuplumab (BMS-936564 / MDX1338): a fully human anti-CXCR4 antibody induces cell death in chronic lymphocytic leukemia mediated through a reactive oxygen species-dependent pathway.
Kashyap MK; Kumar D; Jones H; Amaya-Chanaga CI; Choi MY; Melo-Cardenas J; Ale-Ali A; Kuhne MR; Sabbatini P; Cohen LJ; Shelat SG; Rassenti LZ; Kipps TJ; Cardarelli PM; Castro JE
Oncotarget; 2016 Jan; 7(3):2809-22. PubMed ID: 26646452
[TBL] [Abstract][Full Text] [Related]
15. Recent advances on the use of the CXCR4 antagonist plerixafor (AMD3100, Mozobil™) and potential of other CXCR4 antagonists as stem cell mobilizers.
De Clercq E
Pharmacol Ther; 2010 Dec; 128(3):509-18. PubMed ID: 20826182
[TBL] [Abstract][Full Text] [Related]
16. Clinical significance of chemokine receptor antagonists.
Miao M; De Clercq E; Li G
Expert Opin Drug Metab Toxicol; 2020 Jan; 16(1):11-30. PubMed ID: 31903790
[No Abstract] [Full Text] [Related]
17. Halting metastasis through CXCR4 inhibition.
Ramsey DM; McAlpine SR
Bioorg Med Chem Lett; 2013 Jan; 23(1):20-5. PubMed ID: 23211868
[TBL] [Abstract][Full Text] [Related]
18. Balixafortide plus eribulin in HER2-negative metastatic breast cancer: a phase 1, single-arm, dose-escalation trial.
Pernas S; Martin M; Kaufman PA; Gil-Martin M; Gomez Pardo P; Lopez-Tarruella S; Manso L; Ciruelos E; Perez-Fidalgo JA; Hernando C; Ademuyiwa FO; Weilbaecher K; Mayer I; Pluard TJ; Martinez Garcia M; Vahdat L; Perez-Garcia J; Wach A; Barker D; Fung S; Romagnoli B; Cortes J
Lancet Oncol; 2018 Jun; 19(6):812-824. PubMed ID: 29706375
[TBL] [Abstract][Full Text] [Related]
19. The role of CXCL12 in tumor microenvironment.
Meng W; Xue S; Chen Y
Gene; 2018 Jan; 641():105-110. PubMed ID: 29017963
[TBL] [Abstract][Full Text] [Related]
20. A novel CXCR4 antagonist for hematopoietic stem cell mobilization.
Fricker SP
Expert Opin Investig Drugs; 2008 Nov; 17(11):1749-60. PubMed ID: 18922110
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
